International Clinical Trial: Clinical Efficacy and Economic Analysis of Aflibercept Biosimilar (Zhuochuming(R)) and Ranibizumab Biosimilar (Rimmyrah(R)) in the Treatment of Common Ocular Fundus Diseases

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129032) titled 'Clinical Efficacy and Economic Analysis of Aflibercept Biosimilar (Zhuochuming(R)) and Ranibizumab Biosimilar (Rimmyrah(R)) in the Treatment of Common Ocular Fundus Diseases' on July 29.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Eye Hospital, Wenzhou Medical University

Condition: Neovascular age-related macular degeneration and diabetic macular edema, retinal vein occlusion-related macular edema

Intervention: Eylea (aflibercept) group:None Zhuochuming (aflibercept biosimilar) group:None Lucentis (ranibizumab) group:None

Recruitment Status: Not Recruiting

Phase: N/A

Dat...